UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Corrigendum to “ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe”: Ann Oncol 2016; 27 (8): 1423-1443

Annals of oncology, 2020-11, Vol.31 (11), p.1589-1589

2020

Volltextzugriff (PDF)

133INORAL TUMOUR THERAPY IN EMERGING COUNTRIES: SPECIAL PROBLEMS ENCOUNTERED

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv46-iv46

Eniu, A.

2014

Volltextzugriff (PDF)

Oral Tumour Therapy in Emerging Countries: Special Problems Encountered

Annals of oncology, 2014-09, Vol.25, p.iv46

Eniu, A.

2014

Volltextzugriff (PDF)

Are BRCA1/2 next generation sequencing results comparable across platforms in Europe? A validation study of BRCA testing in Romanian high-risk breast cancer patients

Breast (Edinburgh), 2017-03, Vol.32, p.S32-S32

2017

Volltextzugriff (PDF)

Correction to: 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Annals of oncology, 2017-12, Vol.28 (12), p.3111-3111

2017

Volltextzugriff (PDF)

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

European journal of cancer (1990), 2015-09, Vol.51, p.S263-S264

2015

Volltextzugriff (PDF)

371P Adherence to standardized and structured electronic symptom reporting (ePRO) via mobile app in HER2-positive breast cancer treated with HER2 biosimilar trastuzumab

Annals of oncology, 2023-10, Vol.34, p.S330-S330

2023

Volltextzugriff (PDF)

Hurdles and delays in access to anti-cancer drugs in Europe

Ecancermedicalscience, 2014-11, Vol.8, p.482-482

2014

Volltextzugriff (PDF)

Corrigendum to “ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe”

Annals of oncology, 2020-11, Vol.31 (11), p.1589

2020

Volltextzugriff (PDF)

75P Electronic patient-reported outcomes and machine learning in predicting unplanned visits and hospitalisation rates in cancer patients undergoing systemic therapy

ESMO open, 2023-05, Vol.8 (1), p.101298, Article 101298

2023

Volltextzugriff (PDF)

425P The humanitarian PACT for advanced breast cancer: A multi-stakeholder collaboration to improve access to treatment in low- and middle-income countries

Annals of oncology, 2024-09, Vol.35, p.S397-S398

2024

Volltextzugriff (PDF)

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Annals of oncology, 2017-12, Vol.28 (12), p.3111-3111

2017

Volltextzugriff (PDF)

Generics drugs in oncology: their role in better value health care

Annals of oncology, 2013, Vol.24

2013

Volltextzugriff (PDF)

Abstract P4-06-11: Is myriad a reliable genetic risk model for prediction BRCA1/2 mutations in Romanian high-risk breast cancer patients?

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P4-P4-06-11

2018

Volltextzugriff (PDF)

Is there a link between BRCA1 and BRCA2 mutations and obesity, high blood pressure and diabetes mellitus in Romanian high-risk breast cancer cases?

Annals of oncology, 2017-11, Vol.28, p.x5-x5

2017

Volltextzugriff (PDF)

Understanding BRCA1 and BRCA2 mutated breast cancer cases in Romania: First report on founder mutations in Romanians

Annals of oncology, 2017-09, Vol.28, p.v60-v61

2017

Volltextzugriff (PDF)

71P Patient-reported understanding of biomarkers associated with metastatic breast cancer (mBC) diagnosis: Results from a global mBC survey in 36 countries

ESMO open, 2024-05, Vol.9, p.103077, Article 103077

2024

Volltextzugriff (PDF)

31 Management of breast cancer in limited-resource countries

European journal of cancer supplements, 2009, Vol.7 (2), p.11-11

2009

Volltextzugriff (PDF)

Evaluation of clinical outcomes of her2/neu positive breast cancer patients treated with adjuvant trastuzumab in two oncology centers from middle income coutries

Annals of oncology, 2016-10, Vol.27, p.vi479-vi479

2016

Volltextzugriff (PDF)

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers

ESMO open, 2016-01, Vol.1 (6), p.e000142-e000142, Article e000142

2016

Volltextzugriff (PDF)

3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)

Annals of oncology, 2019-10, Vol.30, p.v63-v64

2019

Volltextzugriff (PDF)

190P3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

190P - 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)

Annals of oncology, 2019-10, Vol.30, p.v63-v64

2019

Volltextzugriff (PDF)

Abstract P4-21-02: Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-02

2017

Volltextzugriff (PDF)

Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-01

2018

Volltextzugriff (PDF)

1 – 25 von 237

Suche als RSS-Feed

Aktive Filter

ThemaHumans

ThemaNeoplasm Staging

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(217)
Mit Volltextzugriff
(212)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(111)
Life Sciences & Biomedicine
(89)
Oncology
(45)
Breast Cancer
(26)
Physical Sciences
(17)
Tumors
(13)
Cancer
(12)
Physics
(12)
Hematology, Oncology And Palliative Medicine
(11)
Technology
(11)
Chemistry
(10)
Plant Science
(10)
Plant Sciences
(10)
Patients
(9)
Biomarkers
(8)
Chemistry, Physical
(8)
Materials Science
(8)
Obstetrics & Gynecology
(8)
Biological And Medical Sciences
(7)
Medical Sciences
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Corrigendum to “ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe”: Ann Oncol 2016; 27 (8): 1423-1443

133INORAL TUMOUR THERAPY IN EMERGING COUNTRIES: SPECIAL PROBLEMS ENCOUNTERED

Oral Tumour Therapy in Emerging Countries: Special Problems Encountered

Are BRCA1/2 next generation sequencing results comparable across platforms in Europe? A validation study of BRCA testing in Romanian high-risk breast cancer patients

Correction to: 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

371P Adherence to standardized and structured electronic symptom reporting (ePRO) via mobile app in HER2-positive breast cancer treated with HER2 biosimilar trastuzumab

Hurdles and delays in access to anti-cancer drugs in Europe

Corrigendum to “ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe”

75P Electronic patient-reported outcomes and machine learning in predicting unplanned visits and hospitalisation rates in cancer patients undergoing systemic therapy

425P The humanitarian PACT for advanced breast cancer: A multi-stakeholder collaboration to improve access to treatment in low- and middle-income countries

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Generics drugs in oncology: their role in better value health care

Abstract P4-06-11: Is myriad a reliable genetic risk model for prediction BRCA1/2 mutations in Romanian high-risk breast cancer patients?

Is there a link between BRCA1 and BRCA2 mutations and obesity, high blood pressure and diabetes mellitus in Romanian high-risk breast cancer cases?

Understanding BRCA1 and BRCA2 mutated breast cancer cases in Romania: First report on founder mutations in Romanians

71P Patient-reported understanding of biomarkers associated with metastatic breast cancer (mBC) diagnosis: Results from a global mBC survey in 36 countries

31 Management of breast cancer in limited-resource countries

Evaluation of clinical outcomes of her2/neu positive breast cancer patients treated with adjuvant trastuzumab in two oncology centers from middle income coutries

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers

3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)

190P3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)

190P - 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)

Abstract P4-21-02: Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA)

Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I

Aktive Filter

Suchergebnisse filtern